FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER (HER2+BC) PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS

被引：0
|
作者：
Bellone, M. [1 ]
Pradelli, L. [1 ]
Sanfilippo, A. [1 ]
Caputo, A. [2 ]
Manevy, M. [3 ]
Zerilli, A. [4 ]
机构：
[1] AdRes HEOR, Turin, TO, Italy
[2] Roche Spa, Monza, Italy
[3] F Hoffmann La Roche Ltd, Delemont, Switzerland
[4] Roche Spa, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC113
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [11] A BUDGET-IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER
    Walter, E.
    Lazic-Peric, A.
    VALUE IN HEALTH, 2018, 21 : S26 - S26
  • [12] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [13] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
  • [14] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [15] Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza
    Jafal, Mohamed
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 511 - 518
  • [16] Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
    O'Shaughnessy, Joyce
    Sousa, Susana
    Cruz, Josefina
    Fallowfield, Lesley
    Auvinen, Paivi
    Pulido, Catarina
    Cvetanovic, Ana
    Wilks, Sharon
    Ribeiro, Leonor
    Burotto, Mauricio
    Klingbiel, Dirk
    Messeri, Dimitri
    Alexandrou, Ari
    Trask, Peter
    Fredriksson, Judy
    Machackova, Zuzana
    Stamatovic, Ljiljana
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 223 - 232
  • [17] Optimising HER2-positive Breast Cancer Treatment: Insights on Subcutaneous Pertuzumab-trastuzumab Transition
    Surekha, S.
    Lamiyan, A. K.
    Khatri, P.
    Patil, A. N.
    CLINICAL ONCOLOGY, 2025, 41
  • [18] Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study (vol 88, 499, 2021)
    Wang, Bei
    Deng, Rong
    Hennig, Stefanie
    Badovinac Crnjevic, Tanja
    Kaewphluk, Monika
    Kagedal, Matts
    Quartino, Angelica L.
    Girish, Sandhya
    Li, Chunze
    Kirschbrown, Whitney P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 571 - 572
  • [19] Impact of subcutaneous versus intravenous administration of pertuzumab and trastuzumab (PH) for the treatment of HER2-positive breast cancer in Montenegro
    Saric, N. Cicmil
    Lekic, S.
    Lakicevic, J.
    Todorovic, V.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S72 - S72
  • [20] The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study
    Shao, Z.
    Huang, T.
    Fan, Z.
    Wang, Y.
    Yan, X.
    Yang, H.
    Wang, S.
    Pang, D.
    Li, H.
    Wang, H.
    Geng, C.
    Huang, L.
    Siddiqui, A.
    Wang, B.
    Xie, B.
    Sun, G.
    Restuccia, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S1431 - S1431
12345